Edition:
India

Allergan plc (AGN.N)

AGN.N on New York Stock Exchange

193.02USD
8 May 2020
Change (% chg)

$0.03 (+0.02%)
Prev Close
$192.99
Open
$193.01
Day's High
$193.38
Day's Low
$191.64
Volume
4,208,109
Avg. Vol
1,314,681
52-wk High
$202.22
52-wk Low
$114.27

Latest Key Developments (Source: Significant Developments)

Abbvie Says Allergan CEO Brent Saunders Has Elected Not To Join Abbvie Board
Wednesday, 6 May 2020 

May 6 (Reuters) - Abbvie Inc ::ABBVIE INC - ALLERGAN'S CURRENT CHAIRMAN AND CEO BRENT SAUNDERS HAS ELECTED NOT TO JOIN ABBVIE BOARD.  Full Article

Abbvie Reports Qtrly Adjusted Earnings Per Share $2.42
Friday, 1 May 2020 

May 1 (Reuters) - Abbvie Inc ::ABBVIE QTRLY GAAP EARNINGS PER SHARE $2.02; QTRLY ADJUSTED EARNINGS PER SHARE $2.42.ABBVIE QTRLY NET REVENUE $8.62 BILLION VERSUS $7.83 BILLION.ABBVIE - UPDATES STANDALONE 2020 GAAP EARNINGS PER SHARE GUIDANCE TO $7.60-$7.70 FROM $7.66-$7.76.Q1 EARNINGS PER SHARE VIEW $2.25, REVENUE VIEW $8.33 BILLION -- REFINITIV IBES DATA.ABBVIE - CONFIRMS STANDALONE 2020 ADJUSTED EARNINGS PER SHARE GUIDANCE RANGE OF $9.61-$9.71.FY2020 EARNINGS PER SHARE VIEW $9.48 -- REFINITIV IBES DATA.ABBVIE - QTRLY GLOBAL HUMIRA NET REVENUE OF $4.70 BILLION, UP 5.8%.ABBVIE - QTRLY INTERNATIONAL HUMIRA NET REVENUE OF $1.05 BILLION, DOWN 14.9% ON REPORTED BASIS, OR 12.8% OPERATIONALLY, DUE TO BIOSIMILAR COMPETITION.ABBVIE - QTRLY GLOBAL IMBRUVICA NET REVENUES WERE $1.23 BILLION, UP 20.6%.ABBVIE - QTRLY U.S. HUMIRA NET REVENUE OF $3.66 BILLION, UP 13.7%.ABBVIE - EXPECTS TO CLOSE PENDING ALLERGAN TRANSACTION IN MAY 2020.ABBVIE - QTRLY REVENUE INCLUDES 240 BASIS POINT STOCKING BENEFIT, QTRLY ADJUSTED. EARNINGS PER SHARE INCLUDES $0.09 STOCKING BENEFIT RELATED TO COVID-19 PANDEMIC.ABBVIE SEES Q2 ADJUSTED. EARNINGS PER SHARE $2.10-$2.16, EXCLUDING ABOUT 53 CENTS OF NON-CASH AMORTIZATION, OTHER SPECIFIED ITEMS.Q2 EARNINGS PER SHARE VIEW $2.25 -- REFINITIV IBES DATA.  Full Article

Allergan Declares Q2 Cash Dividend Of $0.74 Per Ordinary Share
Wednesday, 18 Mar 2020 

March 18 (Reuters) - Allergan plc ::ALLERGAN DECLARES SECOND QUARTER 2020 CASH DIVIDEND OF $0.74 PER ORDINARY SHARE.SETS QUARTERLY CASH DIVIDEND OF $0.74PER SHARE.DIVIDEND WILL BE PAID ON CLOSING DATE OF ABBVIE'S PENDING ACQUISITION OF ALLERGAN.ALLERGAN'S Q2 2020 DIVIDEND WILL BE PAID TO SHAREHOLDERS OF RECORD AT CLOSE OF BUSINESS ON APRIL 16, 2020.  Full Article

Abbvie And Allergan Receive Final European Approval To Close Pending Transaction
Tuesday, 3 Mar 2020 

March 3 (Reuters) - Abbvie Inc ::ABBVIE AND ALLERGAN RECEIVE FINAL EUROPEAN APPROVAL TO CLOSE PENDING TRANSACTION.ABBVIE INC - U.S. FTC CONTINUES TO REVIEW PENDING TRANSACTION, WHICH IS NOT SUBJECT TO SPECIFIC TIMELINE.ABBVIE INC - COMPANIES HAVE ENTERED INTO TIMING AGREEMENT WITH FTC STAFF THAT WOULD LIKELY RESULT IN DECISION BY FTC EARLY IN Q2 2020.  Full Article

CMA Issues Supplementary Objections On Probe Relating To Supply Of Hydrocortisone Tablets In UK
Wednesday, 12 Feb 2020 

Feb 12 (Reuters) - UK's Competition and Markets Authority::CMA - ISSUED SUPPLEMENTARY STATEMENT OF OBJECTIONS ON PROBE OF UNFAIR PRICING, ANTI-COMPETITIVE AGREEMENTS IN SUPPLY OF HYDROCORTISONE TABLETS IN UK.UK'S CMA-STILL PROVISIONALLY SEES LIABILITY FOR AUDEN MCKENZIE'S ALLEGED INFRINGEMENTS ATTRIBUTABLE TO ACCORD-UK & LIABILITY ATTRIBUTABLE TO ALLERGAN.UK'S CMA - ALSO PROVISIONALLY SEES LIABILITY FOR AUDEN MCKENZIE'S ALLEGED INFRINGEMENTS ATTRIBUTABLE TO CINVEN, ACCORD PHARMACEUTICALS & INTAS.  Full Article

AbbVie Expects 2020 Skyrizi Revenue Of ~$1.2 Bln And Rinvoq Revenue Of ~$500 Mln
Friday, 7 Feb 2020 

Feb 7 (Reuters) - Abbvie Inc ::ABBVIE SAYS COMMERCIAL ACCESS FOR NEW RHEUMATOID ARTHRITIS DRUG RINVOQ IS NOW AT MORE THAN 95% - CONF CALL.ABBVIE SAYS COMMERCIAL ACCESS OF NEW PSORIASIS DRUG SKYRIZI IS NOW AT PARITY TO HUMIRA AND ABOVE 95% - CONF. CALL.ABBVIE CFO EXPECTS U.S. HUMIRA SALES TO GROW 9% IN 2020 - CONF. CALL.ABBVIE EXPECTS SKYRIZI GLOBAL REVENUE OF ABOUT $1.2 BILLION AND RINVOQ GLOBAL REVENUE OF ABOUT $500 MILLION IN 2020 - CONF. CALL.ABBVIE SAYS ALLERGAN'S RECENT FINANCIAL PERFORMANCE IS TRACKING SLIGHTLY AHEAD OF WHAT ITS DEAL MODEL HAD PROJECTED " - CONF. CALL.ABBVIE SAYS SYNERGY TARGET OF GREATER THAN $2 BILLION FOR ALLERGAN DEAL IS "AN ACHIEVABLE NUMBER" - CONF. CALL.ABBVIE CEO SAYS COMBINED BUSINESS AFTER ALLERGAN DEAL CLOSES WILL BE DRIVEN BY VOLUME AND NOT PRICE - CONF. CALL.ABBVIE SAYS SKYRIZI AND RINVOQ SHOULD BE ABLE TO EXCEED ITS COMBINED SALES TARGET OF $10 BILLION IN 2025, BUT DOES NOT RAISE THE FORECAST - CONF. CALL.  Full Article

AstraZeneca To Recover Global Rights To Brazikumab From Allergan
Monday, 27 Jan 2020 

Jan 27 (Reuters) - AstraZeneca PLC ::ASTRAZENECA TO RECOVER BRAZIKUMAB (MEDI2070).WILL RECOVER THE GLOBAL RIGHTS TO BRAZIKUMAB (FORMERLY MEDI2070), A MONOCLONAL ANTIBODY TARGETING IL23, FROM ALLERGAN.CO, ALLERGAN WILL TERMINATE THEIR EXISTING LICENSE AGREEMENT AND ALL RIGHTS TO BRAZIKUMAB WILL REVERT TO ASTRAZENECA.ALLERGAN TO FUND UP TO AGREED AMOUNT, ESTIMATED TO BE COSTS TO BE INCURRED BY CO UNTIL DEVELOPMENT FOR BRAZIKUMAB IN CD AND UC.AMGEN IS ENTITLED TO RECEIVE A HIGH SINGLE-DIGIT TO LOW DOUBLE-DIGIT ROYALTY ON SALES OF BRAZIKUMAB IF APPROVED AND LAUNCHED.  Full Article

Abbvie Announces Leadership Team And Creation Of New Business, Allergan Aesthetics, Upon Completion Of Acquisition
Wednesday, 8 Jan 2020 

Jan 8 (Reuters) - Abbvie Inc ::ABBVIE ANNOUNCES LEADERSHIP TEAM AND CREATION OF NEW BUSINESS, ALLERGAN AESTHETICS, UPON COMPLETION OF ACQUISITION.ABBVIE INC - ANNOUNCED CREATION OF A NEW GLOBAL BUSINESS, ALLERGAN AESTHETICS, AN ABBVIE COMPANY.ABBVIE - ALLERGAN AESTHETICS WILL BE LED BY CARRIE STROM.ABBVIE - CREATION OF ALLERGAN AESTHETICS EFFECTIVE UPON EXPECTED Q1 2020 CLOSE OF ALLERGAN ACQUISITION.  Full Article

Allergan's Warner Chilcott And Watson To Pay About $300 Million Under Settlement Agreements
Monday, 6 Jan 2020 

Jan 6 (Reuters) - Allergan plc ::WARNER CHILCOTT AND WATSON RESOLVE ANTITRUST CLASS ACTION LITIGATION WITH DIRECT AND INDIRECT PURCHASERS OF LOESTRIN 24 FE AND MINASTRIN 24 FE.ALLERGAN PLC - ITS WARNER CHILCOTT AND WATSON SUBSIDIARIES HAVE REACHED RESOLUTIONS WITH ALL PLAINTIFFS.ALLERGAN PLC - WILL TAKE A PRE-TAX GAAP CHARGE OF ABOUT $300 MILLION TO ITS Q4 2019 EARNINGS.ALLERGAN - WARNER CHILCOTT & WATSON UNITS CONCLUDE PREVIOUSLY DISCLOSED ANTITRUST LITIGATION IN U.S. DISTRICT COURT FOR DISTRICT OF RHODE ISLAND.ALLERGAN PLC - WARNER CHILCOTT AND WATSON WILL PAY APPROXIMATELY $300 MILLION UNDER SETTLEMENT AGREEMENTS.ALLERGAN - SETTLEMENTS MAKE NO ADMISSION OF WRONGDOING ON PART OF CO AND RESOLVE LITIGATION THAT WAS SCHEDULED TO GO TO TRIAL ON JAN. 6, 2020.  Full Article

Amgen And Allergan Submit Biologics License Application For Abp 798, Biosimilar Candidate To Rituxan® (Rituximab), To FDA
Friday, 20 Dec 2019 

Dec 19 (Reuters) - Amgen Inc ::AMGEN AND ALLERGAN SUBMIT BIOLOGICS LICENSE APPLICATION FOR ABP 798, BIOSIMILAR CANDIDATE TO RITUXAN® (RITUXIMAB), TO U.S. FOOD AND DRUG ADMINISTRATION.  Full Article

AbbVie reports loss as COVID-19 hits Botox sales

July 31 Drugmaker AbbVie Inc reported a loss in the second quarter on Friday, as comparable sales from wrinkle treatment Botox, acquired as part of its $63 billion Allergan Plc deal, slumped due to the impact of the COVID-19 pandemic.

No consensus analysis data available.